Home    Back

Donepezil hydrochloride    (DrugBank: Donepezil)

3 diseases
IDDisease name (Link within this page)Number of trials
6Parkinson disease4
124Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy3
156Rett syndrome1

6. Parkinson disease    [ 2,123 clinical trials,   2,046 drugs,   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways]
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 2,123 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-UMIN000009958
2013/03/0801/03/2013Effects of donepezil on the prognosis of Parkinson's disease with severe olfactory dysfunction Parkinson's diseaseDonepezil hydrochloride added to standard therapy
Placebo added to standard therapy		National Hospital Organization, Sendai-Nishitaga HospitalNULLComplete: follow-up complete55years-old75years-oldMale and Female200Not applicableJapan
2EUCTR2009-015170-35-GB
(EUCTR)		27/01/201221/12/2011Study across 22 UK hospitals investigating if a drug called Donepezil Hydrochloride can help people with an early form of Parkinson's Disease dementia.Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD) - Donepezil in Early Dementia Associated with Parkinson's Disease Parkinson's disease with mild dementia (PDD);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]The Newcastle upon Tyne Hospitals NHS Foundation TrustNULLNot Recruiting Female: yes
Male: yes		500Phase 3United Kingdom
3JPRN-UMIN000005403
2011/04/0108/04/2011A Multi-center Randomized Placebo-controlled Double-blinded Study for the Efficacy of Donepezil against Psychosis in Parkinson Disease Parkinson disease5mg of donepezil hydrochloride
placebo		Designated Research, National Hospital OrganizationNULLComplete: follow-up complete20years-old80years-oldMale and Female142Phase 3Japan
4JPRN-UMIN000003080
2010/01/0130/01/2010Double Blind Study for Effects of Donepezil Hydrochloride on Parkinson's Disease Parkinson's diseaseDonepezil hydrochloride (3mg for 2 weeks, 5mg for 2 weeks)
Placebo		Clinical Research Center, Utano National Hospital, National Hospital OrganizationNULLComplete: follow-up complete40years-old75years-oldMale and Female30Not applicableJapan

124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy    [ 11 clinical trials,   13 drugs,   (DrugBank: 4 drugs),   3 drug target genes,   11 drug target pathways]
Searched query = "Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy", "CADASIL", "Autosomal dominant cerebral artery disease with subcortical infarct and leukoencephalopathy", "Autosomal dominant cerebral artery disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 11 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2004-001162-40-SE
(EUCTR)		01/04/200503/02/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678		Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride		Eisai LtdNULLNot RecruitingFemale: yes
Male: yes		150Finland;United Kingdom;Germany;Spain;Italy;Sweden
2EUCTR2004-001162-40-FI
(EUCTR)		08/03/200528/12/2004An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678		Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride		Eisai LtdNULLNot RecruitingFemale: yes
Male: yes		150Phase 2Finland;Spain;Germany;Italy;United Kingdom;Sweden
3EUCTR2004-001162-40-DE
(EUCTR)		25/01/2005An 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASILAn 18-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of donepezil HCl (E2020) in patients with CADASIL who have cognitive impairment. - Donepezil HCl in CADASIL Cerebral autosomal dominant arteriopathy with subcortical infracts and leukoencephalopathy (CADASIL).CADASIL is a genetic disorder representing a minority of the patients who develop vascular dementia.
MedDRA version: 7.0;Level: PT;Classification code 10057678		Trade Name: Aricept
Product Name: Aricept
Product Code: E2020
INN or Proposed INN: donepezil hydrochloride		Eisai LtdNULLNot RecruitingFemale: yes
Male: yes		150Finland;Spain;Germany;Italy;United Kingdom;Sweden

156. Rett syndrome    [ 36 clinical trials,   49 drugs,   (DrugBank: 19 drugs),   77 drug target genes,   112 drug target pathways]
Searched query = "Rett syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 36 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00069550
(ClinicalTrials.gov)		September 200429/9/2003Independent Studies of Dextromethorphan and of Donepezil Hydrochloride for Rett SyndromePathogenesis of Rett Syndrome: Natural History and TreatmentRett SyndromeDrug: dextromethorphan;Drug: donepezil hydrochlorideEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NULLRecruiting1 Year15 YearsBoth90Phase 3United States

Back to top